New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
10:00 EDTONB, NDZ, ESS, USB, IMO, EIX, MDCO, HSTMOn The Fly: Analyst Downgrade Summary
ArcelorMittal (MT) downgraded to Neutral from Outperform at Credit Suisse... Essex Property Trust (ESS) downgraded to Neutral from Buy at Goldman... Healthstream (HSTM) downgraded to Market Perform from Outperform at Northland... Imperial Oil (IMO) downgraded to Underperform from Neutral at BofA/Merrill... Nordion (NDZ) downgraded to Hold from Buy at Canaccord... The Medicines Co. (MDCO) downgraded to Neutral from Overweight at Piper Jaffray... U.S. Bancorp (USB) downgraded to Hold from Buy at Sandler O'Neill... Old National Bancorp (ONB) downgraded to Hold from Buy at Sandler O'Neill... Edison International (EIX) downgraded to Hold from Buy at Argus.
News For ESS;HSTM;IMO;NDZ;MDCO;USB;ONB;EIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2015
15:37 EDTMDCOFDA panel votes in favor of approval for cangrelor
Subscribe for More Information
09:53 EDTUSBU.S. Bancorp says improving interest rates is "a matter of when, not if"
Subscribe for More Information
09:52 EDTUSBU.S. Bancorp does not expect to have a reduction in force
09:51 EDTUSBU.S. Bancorp says lower NIM due to investment portfolio growth
Subscribe for More Information
08:25 EDTUSBUSB: Repurchase activity lower due conservative credit, underwriting culture
U.S. Bancorp said mortgage repurchase activity is lower than peers due to the conservative credit and underwriting culture. Reports Q1 beginning reserve of $46M and ending reserve of $46M. Reports Q1 mortgages repurchased and make-whole payments of $12M. Comments taken from slides for Q1 earnings conference call.
07:57 EDTMDCOThe FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting
The Committee discusses The Medicines Company's New Drug Application (NDA) 204958 Cangrelor injection for proposed indication of reduction of thrombotic cardiovascular events at a meeting being held at FDA Silver Spring, Maryland offices on April 15 at 8 am. Webcast Link
07:24 EDTUSBU.S. Bancorp sees level of net charge-offs increasing modestly in Q2
07:23 EDTUSBU.S. Bancorp sees total nonperforming assts 'relatively stable' in Q2
Subscribe for More Information
07:20 EDTUSBU.S. Bancorp says 'diversification of business mix has served us well'
Subscribe for More Information
07:19 EDTUSBU.S. Bancorp reports Q1 provision for credit losses $264M
Subscribe for More Information
07:18 EDTUSBU.S. Bancorp reports Q1 EPS 76c, consensus 76c
Subscribe for More Information
07:17 EDTUSBU.S. Bancorp reports Q1 EPS 76c, consensus 76c
Subscribe for More Information
07:01 EDTMDCOThe Medicines Co. stock trading halted today
Subscribe for More Information
06:11 EDTUSBRegulators seek to end 'too big to fail' firms, WSJ reports
Subscribe for More Information
April 14, 2015
15:34 EDTUSBNotable companies reporting before tomorrow's open
Subscribe for More Information
12:58 EDTUSBU.S. Bancorp volatility elevated into Q1 and outlook
Subscribe for More Information
April 13, 2015
11:13 EDTMDCOFDA panel briefing docs look positive for Medicines Co., says Leerink
Subscribe for More Information
10:15 EDTMDCOHigh option volume stocks
Subscribe for More Information
April 10, 2015
07:09 EDTMDCOThe Medicines Co. outlook still upbeat after preannouncement, says RBC Capital
After The Medicines Co preannounced lower than expected Q1 revenue, RBC Capital remains upbeat on the company's outlook, citing what it sees as the success of the company's gram negative franchise, its progress on earlier stage, cardiovascular candidates, and approval of and revenue support from up to four products in the near-term. The firm says the shares are "fundamentally inexpensive," while the company has a number of upcoming catalysts. It trimmed its price target on the shares to $37 from $38 but keeps an Outperform rating on the stock.
06:46 EDTMDCOThe Medicines Co. selloff a buying opportunity, says Leerink
Leerink views the selloff in shares of The Medicines Co. after the company preannounced weaker than expected Q1 revenue as a buying opportunity. The firm expects upcoming pipeline catalysts to create value in 2015. It thinks more visibility into four new products with significant revenue potential will move the stock higher. Leerink believes the preannouncement, driven by hospital customers buying fewer products due to the potential for a generic Angiomax to become available, should not come as a surprise. It keeps an Outperform rating on The Medicines Co.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use